PF-Atlas › Clinical Trials › NCT00217204

An Effectiveness, Safety, and Palatability Study of Pancrelipase Microtablets in Infants and Toddlers With Cystic Fibrosis and Fat Malabsorption

Pancrelipase microtablets · Phase 2

Registry ID
NCT00217204
Phase
Phase 2
Status
Completed
Drug / intervention
Pancrelipase microtablets
Sponsor
McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Start
2005-07
Enrollment
18

About this trial

The purpose of this study is to evaluate the effectiveness and safety of PANCREASE MT (pancrelipase microtablets) to improve steatorrhea (excessive excretion of fat in feces) in infants and toddlers with cystic fibrosis who have pancreatic insufficiency, and to assess whether the consistency of the microtablets is acceptable for swallowing in infants and toddlers

View NCT00217204 on ClinicalTrials.gov →

Explore related

All Pancrelipase microtablets trialsAll IPF trials
Medical disclaimer. This page summarizes public trial data for NCT00217204 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.